Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis

Thorax

Volumn 66, Issue 8, 2011, Pages 680-685

  De Boer, Kaïssa ^a   Vandemheen, Katherine L ^a   Tullis, Elizabeth ^b   Doucette, Steve ^a   Fergusson, Dean ^a   Freitag, Andreas ^c   Paterson, Nigel ^d   Jackson, Mary ^e   Lougheed, M Diane ^f   Kumar, Vijay ^g   Aaron, Shawn D ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e GRAND RIVER HOSPITAL   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g SUDBURY REGIONAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; COLISTIN; DORNASE ALFA; TOBRAMYCIN;

ACUTE DISEASE; ADULT; ARTICLE; BODY MASS; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DEATH; DIABETIC PATIENT; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HUMAN; LUNG FIBROSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; SPUTUM; SYMPTOM;

EID: 79960586834     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2011.161117     Document Type: Article

References (20)

1. Rabin HR, Butler SM, Wohl ME, et al; Epidemiologic Study of Cystic Fibrosis. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37:400-6.
2. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007;62:360-7.
3. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-21. (Pubitemid 20157719)
4. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72. (Pubitemid 34114229)
5. Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med 2005;172:99-104. (Pubitemid 40923320)
6. Goldbeck L, Zerrer S, Schmitz TG. Monitoring quality of life in outpatients with cystic fibrosis: feasibility and longitudinal results. J Cyst Fibros 2007;6:171-8. (Pubitemid 46584463)
7. Robson M, Abbott J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992;47:684-9.
8. FitzGerald JM. Targeting lung attacks. Thorax 2011;66:365-6.
9. Konstan MW, Morgan WJ, Butler SM, et al; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-9.
10. Cystic Fibrosis Foundation Patient Registry 2008. Annual Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation, 2009.
11. Amadori A, Antonelli A, Balteri I, et al. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 2009;103:407-13.
12. Jarad NA, Higgs S, Jeffcote T, et al. Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chron Respir Dis 2005;2:133-7. (Pubitemid 41021090)
13. Aaron SD, Vandemheen KL, Lewis-Giesbrecht T, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010;19:2145-53.
14. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64. (Pubitemid 11117589)
15. Block JK, Vandemheen KL, Tullis E, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax 2006;61:969-74. (Pubitemid 44787167)
16. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52. (Pubitemid 32144560)
17. Marshall BC, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005;146:681-7. (Pubitemid 40616255)
18. Jarad NA, Giles K. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. Chron Respir Dis 2008;5:29-33. (Pubitemid 351903610)
19. Amin R, Dupuis A, Aaron SD, et al. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010;137:171-6.
20. Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8.